125 related articles for article (PubMed ID: 12594299)
1. Anti-idiotype x anti-LFA-1 bispecific antibodies inhibit metastasis of B cell lymphoma.
Cohen S; Haimovich J; Hollander N
J Immunol; 2003 Mar; 170(5):2695-701. PubMed ID: 12594299
[TBL] [Abstract][Full Text] [Related]
2. Anti-idiotype x anti-CD44 bispecific antibodies inhibit invasion of lymphoid organs by B cell lymphoma.
Avin E; Haimovich J; Hollander N
J Immunol; 2004 Oct; 173(7):4736-43. PubMed ID: 15383611
[TBL] [Abstract][Full Text] [Related]
3. Idiotype-specific inhibition of LFA-1-mediated cell adhesion by anti-idiotype x anti-LFA-1 bispecific antibodies.
Kollet O; Haimovich J; Hollander N
Immunol Lett; 1998 Jul; 62(3):171-6. PubMed ID: 9698116
[TBL] [Abstract][Full Text] [Related]
4. T cell costimulus-independent and very efficacious inhibition of tumor growth in mice bearing subcutaneous or leukemic human B cell lymphoma xenografts by a CD19-/CD3- bispecific single-chain antibody construct.
Dreier T; Baeuerle PA; Fichtner I; Grün M; Schlereth B; Lorenczewski G; Kufer P; Lutterbüse R; Riethmüller G; Gjorstrup P; Bargou RC
J Immunol; 2003 Apr; 170(8):4397-402. PubMed ID: 12682277
[TBL] [Abstract][Full Text] [Related]
5. Bispecific anti-idiotype/anti-CD3 antibody therapy of murine B cell lymphoma.
Weiner GJ; Hillstrom JR
J Immunol; 1991 Dec; 147(11):4035-44. PubMed ID: 1834746
[TBL] [Abstract][Full Text] [Related]
6. Rejection of tumors of the B cell lineage by idiotype-vaccinated mice.
Haimovich J; Kukulansky T; Weissman B; Hollander N
Cancer Immunol Immunother; 1999 Feb; 47(6):330-6. PubMed ID: 10203063
[TBL] [Abstract][Full Text] [Related]
7. Idiotype vaccination strategies against a murine B-cell lymphoma: dendritic cells loaded with idiotype and bispecific idiotype x anti-class II antibodies can protect against tumor growth.
Bohlen H; Thielemanns K; Tesch H; Engert A; Wolf HJ; van Camp B; Urbain J; Diehl V
Cytokines Mol Ther; 1996 Dec; 2(4):231-8. PubMed ID: 9384709
[TBL] [Abstract][Full Text] [Related]
8. Immunization with a recombinant adenovirus encoding a lymphoma idiotype: induction of tumor-protective immunity and identification of an idiotype-specific T cell epitope.
Armstrong AC; Dermime S; Allinson CG; Bhattacharyya T; Mulryan K; Gonzalez KR; Stern PL; Hawkins RE
J Immunol; 2002 Apr; 168(8):3983-91. PubMed ID: 11937555
[TBL] [Abstract][Full Text] [Related]
9. In vivo retargeting of T cell effector function by recombinant bispecific single chain Fv (anti-CD3 x anti-idiotype) induces long-term survival in the murine BCL1 lymphoma model.
De Jonge J; Heirman C; de Veerman M; Van Meirvenne S; Moser M; Leo O; Thielemans K
J Immunol; 1998 Aug; 161(3):1454-61. PubMed ID: 9686611
[TBL] [Abstract][Full Text] [Related]
10. Monoclonal anti-idiotype antibodies against the murine B cell lymphoma 38C13: characterization and use as probes for the biology of the tumor in vivo and in vitro.
Maloney DG; Kaminski MS; Burowski D; Haimovich J; Levy R
Hybridoma; 1985; 4(3):191-209. PubMed ID: 3899906
[TBL] [Abstract][Full Text] [Related]
11. A recombinant bispecific single-chain fragment variable specific for HLA class II and Fc alpha RI (CD89) recruits polymorphonuclear neutrophils for efficient lysis of malignant B lymphoid cells.
Guettinger Y; Barbin K; Peipp M; Bruenke J; Dechant M; Horner H; Thierschmidt D; Valerius T; Repp R; Fey GH; Stockmeyer B
J Immunol; 2010 Feb; 184(3):1210-7. PubMed ID: 20042573
[TBL] [Abstract][Full Text] [Related]
12. Treatment of murine B cell lymphoma with bispecific monoclonal antibodies (anti-idiotype x anti-CD3).
Demanet C; Brissinck J; Van Mechelen M; Leo O; Thielemans K
J Immunol; 1991 Aug; 147(3):1091-7. PubMed ID: 1830596
[TBL] [Abstract][Full Text] [Related]
13. Idiotype vaccination post-bone marrow transplantation for B-cell lymphoma: initial studies in a murine model.
Kwak LW; Campbell M; Levy R
Cancer Detect Prev; 1991; 15(4):323-5. PubMed ID: 1794139
[TBL] [Abstract][Full Text] [Related]
14. In vivo treatment with anti-ICAM-1 and anti-LFA-1 antibodies inhibits contact sensitization-induced migration of epidermal Langerhans cells to regional lymph nodes.
Ma J; Wang JH; Guo YJ; Sy MS; Bigby M
Cell Immunol; 1994 Oct; 158(2):389-99. PubMed ID: 7923390
[TBL] [Abstract][Full Text] [Related]
15. In vivo studies using bispecific antibodies (anti-CD3 x anti-idiotype) and CD28-induced costimulation in the BCL1 lymphoma.
Demanet C; Brissinck J; De Jonge J; Thielemans K
J Hematother; 1995 Oct; 4(5):363-8. PubMed ID: 8581370
[TBL] [Abstract][Full Text] [Related]
16. T cell activation and cytokine production in anti-CD3 bispecific antibody therapy.
Belani R; Weiner GJ
J Hematother; 1995 Oct; 4(5):395-402. PubMed ID: 8581375
[TBL] [Abstract][Full Text] [Related]
17. Targeting BCL1 lymphoma with anti-idiotype antibodies: biodistribution kinetics of directly labeled antibodies and bispecific antibody-targeted bivalent haptens.
Manetti C; Rouvier E; Gautherot E; Loucif E; Barbet J; Le Doussal JM
Int J Cancer; 1997 Jun; 71(6):1000-9. PubMed ID: 9185704
[TBL] [Abstract][Full Text] [Related]
18. Trioma-based vaccination against B-cell lymphoma confers long-lasting tumor immunity.
Mocikat R; Selmayr M; Thierfelder S; Lindhofer H
Cancer Res; 1997 Jun; 57(12):2346-9. PubMed ID: 9192805
[TBL] [Abstract][Full Text] [Related]
19. Involvement of LFA-1/intracellular adhesion molecule-1-dependent cell adhesion in CD40-mediated inhibition of human B lymphoma cell death induced by surface IgM crosslinking.
Sumimoto S; Heike T; Kanazashi S; Shintaku N; Jung EY; Hata D; Katamura K; Mayumi M
J Immunol; 1994 Sep; 153(6):2488-96. PubMed ID: 7521364
[TBL] [Abstract][Full Text] [Related]
20. The targeting of CD4+ T lymphocytes to a B cell lymphoma. A comparison of anti-CD3-anti-idiotype antibody conjugates and antigen-anti-idiotype antibody conjugates.
Gravelle M; Ochi A
J Immunol; 1989 Jun; 142(11):4079-84. PubMed ID: 2523940
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
